Skip to content
Journal ArticleAlzheimer's & dementia (Amsterdam, Netherlands)·Aug 2026

Semaglutide Slowed a Blood-Based Dementia Risk Score in Older Heart Patients

Key Insight

This analysis suggests GLP-1 drugs may affect brain-related blood markers, though actual dementia outcomes remain untested.


Older adults with excess weight and heart disease but no diabetes took semaglutide or a placebo for two years. A 25-protein blood test that predicts future dementia risk rose much less in the semaglutide group. This isn't proof of fewer dementia cases, just a slower rise in a risk marker. Still, it adds to the idea that GLP-1 drugs may do something for the aging brain.

Conflict of Interest Disclosure: Two authors work for and own shares in Novo Nordisk, which makes semaglutide; another author consults for Novo Nordisk.

Disclaimer: Research summaries are provided for informational purposes only and do not constitute medical advice. Always consult a qualified healthcare professional before making changes to your health routine.